This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Roche's CEO Hosts Merger And Acquisition Call (Transcript)

Roche (RHHBY.PK)

Merger and Acquisition Call

January 25, 2012, 07:00 a.m. ET

Executi ve s

Severin Schwan - CEO, Roche Group

Alan Hippe - Chief Financial and IT Officer

Dan O'Day - Diagnostics Division, COO and Member of the Roche Corporate Executive Committee

Analyst s

Sachin Jain - Bank of America/Merrill Lynch

Gbola Amusa - UBS

Bill Quirk - Piper Jaffray

Quintin Lai - Robert W. Baird

Vincent Meunier - Exane BNP Paribas

Alexandra Hauber - JP Morgan

Luisa Hector - Crédit Suisse

Michael Leacock - RBS

Keyur Parekh - Goldman Sachs

Presentation

Severin Schwan

Welcome to everybody, and thank you for joining our call, which is going to last for about one hour. This is Severin speaking, and with me today, Alan Hippe, our Chief Financial Officer; and Dan O’Day, Chief Operating Officer of Roche Diagnostics.

Illumina is a great successful company, and we are excited to share with you the background of this planned acquisition. At the beginning, just let me shortly put this transaction into context. An important element of today’s success of Roche Diagnostics is our breadth and depth of various key measuring technologies. They allow us to develop and market a broad range of diagnostic tests from molecular diagnostics to serum work area or tissue diagnostic testing. The completeness of our offering is important, both for our customers and Roche.

Over the years, we have developed a number of high-tech platforms, both internally and also as you can see on Page 4, by acquiring a number of key technologies. And we believe that sequencing is and will continue to be an increasingly important technology as we go forward.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,976.13 -61.84 -0.34%
S&P 500 2,100.04 -8.88 -0.42%
NASDAQ 5,024.5320 -35.7140 -0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs